Compare DNP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNP | DNTH |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.6B |
| IPO Year | 1995 | 2018 |
| Metric | DNP | DNTH |
|---|---|---|
| Price | $10.70 | $86.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $121.00 |
| AVG Volume (30 Days) | ★ 636.5K | 492.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.59 | $16.77 |
| 52 Week High | $10.84 | $96.50 |
| Indicator | DNP | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 50.54 |
| Support Level | $9.93 | $82.00 |
| Resistance Level | N/A | $88.45 |
| Average True Range (ATR) | 0.10 | 4.42 |
| MACD | -0.02 | -0.90 |
| Stochastic Oscillator | 53.97 | 44.24 |
DNP Select Income Fund Inc is a closed-ended investment management fund. Its investment objectives are current income and long-term growth of income, with capital appreciation as a secondary objective. The Fund seeks to achieve its investment objectives by investing mainly in a diversified portfolio of equity and fixed-income securities of companies in the public utilities industry. Under normal market conditions, more than 65% of the Fund's total assets are invested in securities of public utility companies engaged in the production, transmission, or distribution of electric energy, gas, or telephone services.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.